Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS

European Respiratory Journal, Supplement

Volumn 22, Issue 42, 2003, Pages

  Meduri, G U ^a   Carratu, P ^a   Freire, A X ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Biology; Glucocorticoid; Glucocorticoid receptor; Nuclear factor B; Outcome

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; CIRCULATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; FIBROGENESIS; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFLAMMATION; LONG TERM CARE; LONGITUDINAL STUDY; LUNG FIBROSIS; LUNG STRUCTURE; MORPHOLOGY; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; RESPIRATORY DISTRESS SYNDROME; REVIEW; STRUCTURE ANALYSIS; TREATMENT FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD; METABOLISM; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; GLUCOCORTICOIDS; HUMANS; NF-KAPPA B; RECEPTORS, GLUCOCORTICOID; RESPIRATORY DISTRESS SYNDROME, ADULT; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 0642306996     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage - the role of oxygen, shock, and related factors. A review. Am J Pathol 1976; 85: 209-228.
2. Meduri GU. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996; 9: 2650-2670.
3. Cotran RS, Kumar V, Robbins SL. Cellular injury and cellular death. In: Cotran RS, Kumar V, Robbins SL, eds. Pathologic basis of disease. 5th Edn. Philadelphia, W.B. Saunders, 1994; pp. 1-34.
4. Steinberg KP, Hudson LD. Acute lung injury and acute respiratory distress syndrome. The clinical syndrome. Clin Chest Med 2000; 21: 401-417.
5. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999; 20: 435-459.
6. Meduri GU, Chinn AJ, Leeper KV, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest 1994; 105: 1516-1527.
7. Meduri GU, Eltorky M, Winer-Muram HT. The fibroproliferative phase of late adult respiratory distress syndrome. Semin Respir Infect 1995; 10: 154-175.
8. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-723.
9. 2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. Chest 1989; 96: 849-851.
10. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565-1570.
11. Meduri GU. Host defense response and outcome in ARDS. Chest 1997; 112: 1154-1158.
12. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997; 111: 1306-1321.
13. Shanley TP, Wong HR. Signal transduction pathways in acute lung injury: NF-κB and AP-1. In: Wong HR, Shanley TP, eds. Molecular Biology of Acute Lung Injury, Molecular and Cellular Biology of Critical Care Medicine. Boston, Kluwer, 2001; pp. 1-16.
14. Ross SD, Kron IL, Gangemi JJ, et al. Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-kappaB. Am J Physiol Lung Cell Mol Physiol 2000; 279: L528-536.
15. Lentsch AB, Czermak BJ, Bless NM, Van Rooijen N, Ward PA. Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am J Respir Cell Mol Biol 1999; 20: 692-698.
16. Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000; 117: 1482-1487.
17. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-663.
18. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
19. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-142.
20. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
21. Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993; 12: 3879-3891.
22. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993; 132: 946-952.
23. Hermus AR, Sweep CG. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990; 37: 867-871.
24. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996; 17: 245-261.
25. Didonato JA, Saatcioglu F, Karin M. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996; 154: S11-15.
26. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
27. Wissink S, van Heerde EC, vand der Burg B, van der Saag PT. A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol 1998; 12: 355-363.
28. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes, IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-9563.
29. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100: 2443-2448.
30. Shames BD, Selzman CH, Meldrum DR, et al. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 1998; 10: 389-394.
31. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310: 82-88.
32. Poppers DM, Schwenger P, Vilcek J. Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of I kappa B-alpha. J Biol Chem 2000; 275: 29587-29593.
33. Sheppard KA, Phelps KM, Williams AJ, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CRE-binding protein and steroid receptor coactivator-1. J Biol Chem 1998; 273: 29291-29294.
34. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
35. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351-1362.
36. Melby JC, Spink WW. Comparative studies on adrenalcortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. Journal of Clinical Investigation 1958; 37: 1791-1798.
37. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993; 77: 151-156.
38. Briegel J, Forst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock. Lancet 1991; 338: 507-508.
39. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283: 1038-1045.
40. Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998; 114: 355-360.
41. Kass EH, Finland M. Adrenocortical hormones and the management of infection. Ann Rev Med 1957; 8: 1-18.
42. Chrousos GP, Detera-Wadleigh SD, Karl M. Syndromes of glucocorticoid resistance. Annals of Internal Medicine 1993; 119: 1113-1124.
43. Lamberts SW, Koper JW, Biemond P, den Holder FH, de Jong FH. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab 1992; 74: 313-321.
44. Lane SJ, Lee TH. Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid-resistant bronchial asthma. Am Rev Respir Dis 1991; 143: 1020-1024.
45. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93: 33-39.
46. Adcock IM, Lane SJ, Brown CR, Peters MJ, Lee TH, Barnes PJ. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154: 3500-3505.
47. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995; 152: S125-140.
48. Norbiato G, Bevilacqua M, Vago T, et al. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 608-613.
49. Molijn GJ, Spek JJ, van Uffelen JC, et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995; 80: 1799-1803.
50. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB, Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991; 146: 3523-3527.
51. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151: 3460-3466.
52. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol 1996; 157: 2654-2659.
53. 2 in sheep with acute lung injury after high dose endotoxin infusion. Am Rev Respir Dis 1993; 148: 878-881.
54. Fan J, Gong XQ, Wu J, Zhang YF, Xu RB. Effect of glucocorticoid receptor (GR) blockade on endotoxemia in rats. Circ Shock 1994; 42: 76-82.
55. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997; 65: 111-137.
56. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107: 1062-1073.
57. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A, Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995; 108: 1303-1314.
58. Golden E, John B, Stentz F, Tolley EA, Meduri GU. Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Shock 2000; 13: 42S.
59. Headley AS, Meduri GU, Tolley E, Stentz F. Infections, SIRS, and CARS during ARDS and in response to prolonged glucocorticoid treatment. Am J Respir Crit Care Med 2000; 161: A378.
60. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158: 1432-1441.
61. Carratu P, Quasney MW, Stentz FB, et al. TNF-a and LT-a gene polymorphism in acute respiratory distress syndrome (ARDS). Am J Respir Crit Care Med 2002; 165: A474.
62. Weigelt JA, Norcross JF, Borman KR, Snyder WHD. Early steroid therapy for respiratory failure. Arch Surg 1985; 120: 536-540.
63. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987; 92: 1032-1036.
64. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-68.
65. Meduri GU. An historical review of glucocorticoid treatment in Sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis 1999; 3: 21-38.
66. Hesterberg TW, Last JA. Ozone-induced acute pulmonary fibrosis in rats. Prevention of increased rates of collagen synthesis by methylprednisolone. Am Rev Respir Dis 1981; 123: 47-52.
67. Hakkinen PJ, Schmoyer RL, Witschi HP. Potentiation of butylated-hydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am Rev Respir Dis 1983; 128: 648-651.
68. Kehrer JP, Klein-Szanto AJ, Sorensen EM, Pearlman R, Rosner MH. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis 1984; 130: 256-261.
69. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg 1985; 120: 530-535.
70. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990; 97: 138-143.
71. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999-2006.
72. Meduri GU, Headley S, Carson S, Umberger R, Kelso T, Tolley E. Prolonged methylprednisolone treatment improves lung function and outcome of unresolving ARDS. A randomized, double-blind, placebo-controlled trial. JAMA 1998; 280: 159-165.
73. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A, Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 1995; 108: 1315-1325.
74. Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. South Med J 1996; 89: 359-364.
75. Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC Jr, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995; 170: 591-595.
76. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, el Torky M, Leeper KV, Jr. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991; 100: 943-952.
77. Meduri GU, Belenchia JM, Massie JD, Eltorky M, Tolley EA. The role of gallium-67 scintigraphy in diagnosing sources of fever in ventilated patients. Intensive Care Med 1996; 22: 395-403.
78. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165: 983-991.
79. Stentz F, Tolley EA, Headley AS, Chrousos GP, Meduri GU. Mechanisms of NF-κB and glucocorticoid receptor (GRα) in activation and regulation of systemic inflammation (SI) in ARDS. Am J Respir Crit Care Med 2001; 163: A450.